Sinopharm Anhui Medical Technology - Raised $52.8M Funding

5 days ago · Sinopharm Anhui Medical Technology has raised a total funding of $52.8M over 3 rounds from 3 investors. Investors include Qianhai Ark Asset Management, Jifu Venture …

CouponFollow Extension

$52
OFF

Sinopharm Anhui Medical Technology - Raised $52.8M Funding

4 weeks from now

5 days ago · Sinopharm Anhui Medical Technology has raised a total funding of $52.8M over 3 rounds from 3 investors. Investors include Qianhai Ark Asset Management, Jifu Venture …

tracxn.com

$52
OFF

Sinopharm Anhui Medical Technology - Company Profile - Tracxn

4 weeks from now

Sinopharm Anhui Medical Technology - Provider of hospital materials management and construction services. Raised a total funding of $52.8M over 3 rounds from 3 investors. …

tracxn.com

7%
OFF

Sinopharm Is The Largest Drugs And Medical Devices

4 weeks from now

Aug 27, 2024 · As the largest medical distributor, Sinopharm has been growing at a 10-year compound annual growth rate, or CAGR, of 10.7%, with both industry expansion and industry …

morningstar.com

32%
OFF

Exclusive: Sinopharm-led Consortium Plans $3.3 Billion Take …

4 weeks from now

Jan 27, 2021 · Sinopharm holds 32% of China TCM, while Ping An has 12% and Wang 5.4%. The consortium is looking for financial investors to join the take-private bid, the sources said. It …

reuters.com

$10
OFF

Shanghai Longhui Medical Technology - Raised Funding From 2

4 weeks from now

Nov 1, 2024 · Findable - Oslo based, raised a funding of $10.1M in Series A round held on 26 Sep, 2024. thisisyouni.co.uk - raised a funding of $1.01M in Seed round held on 26 Sep, 2024. …

tracxn.com

FAQs about Sinopharm Anhui Medical Technology - Raised $52.8M Funding Coupon?

How will China's medical-device industry evolve after MIC2025?

The government then initiates policies to grow domestic industries that can challenge global firms (see go.nature.com/49rlyhv). China’s ambitions for its medical-device industry look no different. A profusion of policy and fiscal initiatives to boost local production and use of medical devices appeared after MIC2025. ...

Is Sinopharm a publicly traded company?

Sinopharm holds a controlling stake in six publicly traded entities — two listed in Hong Kong, including Sinopharm Holdings, and four on the Chinese mainland. Despite limited uptake so far outside China, Sinopharm has wasted little time in expanding its ability to manufacture the Covid-19 vaccines. ...

Is Sinopharm a foreign policy tool?

Sinopharm directed requests to comment to the Communist party, which did not respond. With governments jostling for a finite supply of vaccines, the race to inoculate billions is a bruising and highly political one. Beijing has made little secret that Sinopharm’s jab doubles up as a foreign policy tool. ...

Does Sinopharm's jab double up as a foreign policy tool?

Beijing has made little secret that Sinopharm’s jab doubles up as a foreign policy tool. In February, Sinopharm’s deliveries, some donated by Beijing, included 500,000 for Pakistan, 600,000 for Cambodia and 300,000 each for Peru and Laos. ...

How will China's medical-device strategy affect the medical-technology industry?

The push intensified further in 2021, in the hope of slashing costs and meeting the evolving health-care needs of an ageing population, while also boosting innovation and enhancing national security by curtailing imports. The strategy is affecting both China’s medical-device sector and the medical-technology industry as a whole. ...

Is China becoming more self-sufficient in health-care products?

State-owned firms looking to procure such items must ensure that the equipment is made of 25–100% of locally manufactured parts. Order 551 must be viewed in the broader context, says Chen, “which is that China, in general, is trying to be much more self-sufficient in its health-care products”. ...